Anthony W. Tolcher and Phase - Free people check

(1 - 19 from 30

)

NextCure to Present Clinical Data from NC318 Phase

ir.nextcure.com

Lead Author: Anthony Tolcher , MD, FRCPC, FACP, Director of Clinical Research, NEXT Oncology. About NC318 NC318 is a first-in-class immunomedicine against ... › news-release-details › nextcure...

Heat Biologics Announces Initiation of the Lead Clinical Trial ...

www.heatbio.com

18 Jun — Anthony Tolcher, M.D., FRCPC, a medical oncologist and co-founder of NEXT Oncology, has been appointed the lead investigator for the Phase › news-releases › detail › heat...

Formation Biologics Announces Dosing of First Patient in a ...

www.prnewswire.com

15 May — ... in a Phase I/IIa Trial of AVID100, Closing of Series B Financing, and Appointment of Dr. Anthony Tolcher to its Board of Directors ... › news-releases › formatio...

Anthony TOLCHER | Director of Clinical Research | Phase I

www.researchgate.net

› profile › Anthony-Tolcher-2

Scientific Advisory Board - Elucida Oncology, Inc.

www.elucidaoncology.com

Anthony Tolcher M.D. FRCPC FACP. Dr. Tolcher is CEO and Founder of NEXT OncologyTM, San Antonio, Texas, a newly founded Phase I group that seeks to ... › about › scientific-a...

Phase II Study of the Mammalian Target of Rapamycin Inhibitor...

hwmaint.jco.ascopubs.org

Sant P. Chawla, Arthur P. Staddon, Laurence H. Baker, Scott M. Schuetze, Anthony W. Tolcher, Gina Z. D'Amato, Jean-Yves Blay, Monica M. Mita,

A phase I trial of LY tosylate, a p70 S6 kinase inhibitor, in...

www.sciencedirect.com

Anthony Tolcher,; Jonathan Goldman,; Amita Patnaik,; Kyriakos P. Papadopoulos,; Paul Westwood,; Claudia S. Kelly,; William Bumgardner,; Lillian Sams, ...

Phase 1 and pharmacokinetic study of LY , a p38 MAPK inhibitor,...

www.ncbi.nlm.nih.gov

Anthony Tolcher has served on the following advisory and consulting boards: Astex, Bayer, BioInvent, Boehringer-Ingelheim, Celldex, EMD ...

Phase I Dose-Escalation Study of EZN (PEG-SN38), a Novel...

www.ncbi.nlm.nih.gov

Employment and Stock Ownership: Aby Buchbinder, Enzon. Advisory Role: Anthony Tolcher (Uncompensated). Honoraria: François Lokiec ...

A golden era of cancer clinical trials | Nature Medicine

www.nature.com

7 days ago — In San Antonio, Texas, Anthony Tolcher has been a principal investigator for 20 phase 1 clinical studies of FDA-approved cancer drugs, ... › nature medicine › news feature

Heat Biologics Announces Initiation of the Yahoo Finance

finance.yahoo.com

18 Jun — Anthony Tolcher, M.D., FRCPC, a medical oncologist and co-founder of NEXT Oncology, has been appointed the lead investigator for the Phase › news › heat-biologics-anno...

Forbius Announces Dosing of First Patient in a Phase I/IIa Trial ...

forbius.com

Anthony Tolcher to its Board of Directors . (May 15, 2017) - Forbius (Formation Biologics), a clinical ... › press-releases › formation-bio-ann...

Abstract #3503 A Phase I Study of MK-2206, an Oral Potent Allosteric...

slideplayer.com

A Phase I Study of MK-2206, an Oral Potent Allosteric Akt Inhibitor in Patients with Advanced Solid Tumors Anthony W. Tolcher, 1 Timothy A. Yap, 2 Ivy.

A First-in-Human Phase I Study of OPB , a Small-Molecule STAT3...

mayoclinic.pure.elsevier.com

Anthony Tolcher, Keith Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas Witzig, Thomas Habermann, Andrea Bullock, Edwin Rock, Agnes ...

About NEXT Oncology - NEXT Oncology

nextoncology.com

NEXT Oncology, founded by Anthony W. Tolcher, M.D., FRCPC, is a Phase 1 center dedicated to providing options for advanced cancer patients and advancing cancer...

A first-in-human phase i study of the oral p38 MAPK inhibitor,...

mayoclinic.pure.elsevier.com

Amita Patnaik, Paul Haluska, Anthony W. Tolcher, Charles Erlichman, Kyriakos P. Papadopoulos, Janet L. Lensing, Muralidhar Beeram, Julian R. Molina, Drew W. Rasco, Rebecca R. Arcos, Claudia S. Kelly, Sameera R. Wijayawardana, Xuekui Zhang, Louis F. Stancato, Robert Bell, Peipei Shi, ...

APExBIO - Amuvatinib (MP-470, HPK 56)|Tyrosine kinase inhibitor|CAS#...

www.apexbt.com

Raoul Tibes, Gil Fine, Gavin Choy, Sanjeev Redkar, Pietro Taverna, Aram Oganesian, Amarpao Sahai, Mohammad Azab and Anthony W. Tolcher. A phase I ...

Utomilumab/Pembrolizumab Combo Shows Responses in Different Solid...

www.targetedonc.com

Anthony W. Tolcher, MD. Adding utomilumab (PF ), a 4-1BB agonist, to pembrolizumab (Keytruda), a PD-1 inhibitor, was shown to be a safe and effective combination therapy for patients with different types of advanced solid tumors, according to findings from a phase Ib study presented at the ...

Conference Calendar - TAT 2018

cslide.ctimeetingtech.com

46O - Introduction and presentation of: A Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate. Presentation Number. 46O. Lecture Time. 15: :30. Speakers. Anthony Tolcher (San Antonio, US). Session Name. ADC payloads. Location. Room Scene AB, Paris Marriott Rive Gauche, Paris, France. Date.

All web results to the name "Anthony W. Tolcher"

Related search requests for Anthony W. Tolcher

Monica Mita

People
Forename "Anthony" (61899)
Name "Tolcher" (48)

sorted by relevance / date

Advanced Search

Search name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Anthony W. Tolcher and Phase Free People Check